Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Inclusion Criteria: 1. Willingness to complete the informed consent process and to comply with study procedures and visit schedule; 2. Men and women aged 8-75; 3. Participants diagnosed with chronic (\>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP; 4. The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP; 5. Platelet count \<30 x 109 / L; 6. If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening); 7. The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant; 8. Willingness to use effective and reliable methods of contraception throughout the entire study period; Exclusion Criteria: 1. All subjects with diseases which may cause secondary immune thrombocytopenia 2. Patients with preventive splenectomy; 3. Hemostatic disorders other than chronic thrombocytopenia; 4. Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for \> 3 consecutive days within 2 weeks of the study start and until the end of the study; 5. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts; 6. Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy; 7. Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment; 8. History of thrombosis or presence of significant risk factors for thrombosis; 9. Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system; 10. Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal); 11. Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex; 12. Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study; 13. Human immunodeficiency virus (HIV) seropositivity, Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive, Patients with hepatitis C (HCV-RNA quantitative test results positive), Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections; 14. Patients with severe history of allergy or allergic constitution; 15. Pregnancy and lactation; 16. History of mental illness and known alcohol/drug addiction; 17. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan; 18. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;